| Company* | Product | Description | Indication | Status |
| | ||||
| CANCER |
||||
| Novogen | Phenoxodiol | Oral formulation | Prostate cancer | Company will begin a clinical trial in Australia (8/20) |
| Supratek Pharma | SP1049C | Combination of doxorubicin and Supratek's Biotransport carrier technology | Advanced cancer | Company is ready to start Phase II trials in Europe and the UK, following positive Phase I results (8/22**) |
| CARDIOVASCULAR | ||||
| Texas | Argatroban | Anticoagulant therapy; synthetic direct thrombin inhibitor that blocks the activity of thrombin | Heparin-induced thrombocytopenia syndrome | The Canadian Therapeutics Products Program issued approval of Argatroban as an anticoagulant therapy (8/1) |
| INFECTION |
||||
| SciClone | Zadaxin | Lead immune system enhancer drug | Hepatitis B | SciClone completed enrollment in its Phase III trial in Japan (8/22) |
| SkyePharma | DepoCyte | Cytarabine liposome injection | Lymphomatous meningitis | European Commission granted marketing authorization in the European Union (8/8) |
| MISCELLANEOUS | ||||
| Biotissue | BioSeed-S | Skin product generated from a patient's own tissue | Chronic venous leg ulcers | Company started a study with 240 patients at 25 centers in Europe (8/8**) |
| Discovery | Surfaxin | Lucinactant; humanized lung surfactant | Meconium aspiration syndrome in full-term newborns | Company was awarded orphan product designation from the European Agency for the Evaluation of Medicinal Products for Surfaxin (8/9) |
| Genaera | Lomucin | Intended to block the hCLCA1-dependent mucus overproduction present in asthma | Asthma | Company initiated the first clinical trial in Mexico (8/16) |
| Genzyme | Fabrazyme | Agalsidase beta enzyme replacement therapy | Fabry disease | Genzyme received orphan drug status approval to market Fabrazyme in the European Union (8/3) |
| Genzyme | Renagel | Phosphate binder for patients with end-stage renal disease on dialysis | End-stage renal disease | Genzyme received approval to market Renagel in Brazil (8/15) |
| Transkaryotic | Replagal | Agalsidase alfa enzyme replacement therapy | Fabry disease | TKT received orphan drug status approval to market Replagal in the European Union (8/3); the Norwegian Medicines Agency granted marketing authorization (8/16) |
| | ||||
Notes: | ||||
* Privately held; ** Denotes the date the item ran in BioWorld International | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange | ||||
